https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 5(2):7-11, 2025

©RIJBAS Publications ISSN: 1597-2879

https://doi.org/10.59298/RIJBAS/2025/52711

Understanding Antimicrobial Resistance: Global Responses Needed

Omutindo Nyakayo A.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Antimicrobial resistance (AMR) is a critical global public health challenge threatening modern medicine's foundations. Resistance emerges from the misuse and overuse of antimicrobials in human medicine, food production, and environmental contamination. The rising prevalence of drug-resistant pathogens exacerbates healthcare inequalities and strains healthcare systems worldwide. Current global initiatives focus on surveillance, research, and promoting responsible antimicrobial use. However, progress is hindered by economic disincentives, regulatory disparities, and limited access to diagnostics and treatment in low-income regions. Addressing AMR requires a "One Health" approach encompassing coordinated global efforts, equitable healthcare access, and innovative solutions in diagnostics, treatment, and prevention. A unified response from governments, industries, and academia is imperative to mitigate the AMR crisis and safeguard public health and sustainable development.

Keywords: Antimicrobial resistance, public health, global initiatives, One Health approach, drug-resistant pathogens.

INTRODUCTION

Antimicrobial resistance (AMR) is currently considered one of the most urgent global problems for public health, and it has the potential to undermine the foundations of modern medicine and threaten all areas of current health care. The term “antimicrobial” is used to designate substances that kill or inhibit the action of microorganisms. There are three kinds of antimicrobial drugs, namely antivirals, which combat viruses; antifungals, which take care of fungi; and, lastly, antibiotics, which treat bacterial infections and are the most commonly used. Antimicrobials are also called anti-infectives. However, especially in the older literature, the terms antibacterials and antibiotics have also been used interchangeably [1, 2]. AMR can be found in numerous pathogens such as bacteria, viruses, protozoa, helminth parasites, and fungi, with the most common being resistance in bacterial populations. The ten most dangerous bacteria in the world already show either severe or threatened AMR. The world’s second-biggest panic is worrying that current viral pandemics are spreading increasingly resistant strains. As a result, AMR can make currently available treatments useless, making common illnesses more difficult to treat and leading to a growing number of deaths. As doctors have much smaller options and tools with which to treat illnesses and diseases, the signals mount that a country’s healthcare delivery system is deteriorating. More efficient antimicrobial management is a critical part of the development of a resilient healthcare delivery system [3, 4].

Factors Contributing to Antimicrobial Resistance

Antimicrobial resistance (AMR) is driven by the use (or more accurately, overuse and misuse) of antibiotics. Two major problems facing humans relate to this. The first is the use and inappropriate use of antibiotics in human medicine. The second is the widespread use and misuse of antibiotics in food production. Suboptimal treatment for human bacterial infections is relatively common, and the widespread treatment of animals with antibiotics, whose use is not justified by the clinical requirement, results in microbial contamination of food products that lead to illness in humans. Several socioeconomic factors influence how antibiotics are used and how resistance patterns emerge. These include access to antibiotics, the wealth of individuals, the sophistication of healthcare systems, and the provision of public health measures [5, 6]. Resistance in livestock may have two impacts on human health. First, by

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

facilitating resistance in zoonotic disease-causing bacteria of the food-producing animal, it can put farmworkers and consumers of these foodstuffs at risk; second, resistant zoonotic bacteria from these animals may cause illness in humans with the same potential for treatment failure. The development of bacterial AMR on the farm may be facilitated by many different environmental factors. Infection with AMR strains of viruses and parasites, or the occurrence of AMR fungi in food-production animals, is possible but is not as serious as the concern regarding resistant bacteria due to the potential transmission of resistance through the food chain. Pollution brought about by industrial agriculture is also a serious problem, whereby sewage and other effluents discharge antibiotic residues on a mass scale into the environment, promoting a high background level of resistance. Large-scale water contamination, most notably combined with poor and overcrowded living conditions, necessitates less controlled antibiotic use, enabling the ready ecological spread of any resistant organisms [7, 8].

Current Global Efforts and Initiatives

Many global organizations are making significant efforts to understand and mitigate antimicrobial resistance (AMR). Several initiatives have already begun to draft action plans and surveys, based on available data, that are geared toward addressing the critical issue of surveillance, research, and public information on AMR [9, 10]. Several international collaborations are attempting to create global repositories of antibiotic resistance patterns from human, animal, and finished food commodities. Various groups are pouring a great deal of energy and resources into the development and promotion of improved practices of antibiotic use on the part of professionals and patients. Additionally, new drugs are in development, as well as new options for treating infections and controlling disease. Such activity is largely international and is progressing, and, as a result, there is a strong opening ground for further global efforts to attempt to address the central issue of twinning access to medicine and the control of infectious diseases [11, 12].

Challenges and Future Directions

Although global action to address AMR has been lacking for many years, there is increasing awareness of the problem. Acknowledging the importance of the problem, however, does not alleviate the complexities and barriers to combating it. Economic challenges arise because it is not always financially rewarding for pharmaceutical companies to devote resources to developing new antimicrobials. Blockbuster drugs for chronic illnesses can be sold to large numbers of patients over extended periods. In contrast, most antimicrobials are taken for a short course and are thus less profitable [13, 14]. Another economic challenge comes from regulations that vary around the world. Some regulations discourage GPs from prescribing broad-spectrum antibiotics, while in some regions, fluoroquinolones can be prescribed for simple urinary tract infections, meaning that the potential market for a new narrow-spectrum antibiotic is limited. Healthcare disparity between regions is a key challenge because even if an effective antimicrobial is developed, it will not be available for people in low-income countries because of financial inaccessibility unless heavily discounted. Raised awareness about AMR is still a necessity as infection prevention and diagnostic stewardship are poorly understood and frequently lacking in healthcare. New technologies in diagnostics are urgently needed; ideally, an inexpensive diagnostic test for manufacture and use in any setting that identifies the pathogen and gives some indication of the effective treatment would be desirable. This would discourage unnecessary antibacterial use based on clinical diagnosis alone. New innovations in diagnostics and many other sectors are currently being explored, and it is hoped that the necessary resources will be supplied for their translation, as well as for subsequent widespread implementation. Further research on AMR at the health system level, visioning scenarios of the future, and prospective national plans or strategies is also warranted. Epidemiologic studies following comprehensive antimicrobial usage and costs in low-middle-income countries are also needed [15, 11]. There is a grave risk to health systems associated with AMR, with the potential for reverting to a pre-antibiotic era where such procedures as knee replacements or chemotherapy also pose an AMR-related risk. A call for coordinated responses and a "One Health" approach has been made, as needs health equity and global access to sustainable antimicrobials. The production of antimicrobials is but one aspect of AMR management, and partnerships that bring industry, academia, and governments together to find sustainable solutions to the AMR crisis are essential. Measurements and outcomes to address several challenges for AMR-related problems were adopted, targeting inherent incentivization, and internal insights were implemented. Finally, new anti-infectives are difficult to bring to market and have been unsuccessful in recent times, resulting in a global plea for broader systems collaborations. Incentives abound for several types of new anti-infectives, the proposition of which is predicted to signal some hope of an improved antimicrobial range. A well-targeted combination of economic knowledge, a broad focus,

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and a realistically guided set of complementary multifaceted approaches is urgently required for global AMR action. Otherwise, issues such as poverty and lack of access to water or vaccines cannot be expected to fully alter the AMR landscape. The ongoing challenge of combating AMR against this combined burden of incomplete knowledge and awareness calls for an urgent set of innovative responses and collaborations that leave no new challenges unturned [16, 17].

Call For Action

Antimicrobial resistance (AMR) is an urgent global challenge demanding action. We must strive to better understand resistance, to know who it is happening to and in which organisms, to appreciate the implications of resistance on the lives of individuals and animals, and to address the resistance-related challenges that constrain our ability to protect health as well as to build food and fiber security. We need more information and we need the ability to monitor the trajectory of resistance not only in laboratories but also in large populations. Without these data, available for use by all, we are managing resistance by guesswork, and we are blind to the most effective actions to mitigate resistance-associated risks [18, 19]. There is a collective responsibility not just for governments and intergovernmental leadership, but also for research funders and policymakers to assist healthcare providers, clinical laboratorians, and scientists to move resistance data and the research efforts required to fill critical knowledge gaps into bold, collaborative action at global, regional, and national levels. In all countries, resistance reduction and the enhancement of political, healthcare, consumer, and commercial strategies to diminish unnecessary antibiotic use, minimize drug-resistant pathogens entering waste streams and the environment, and create a set of economic models that do not risk growth in economic poverty due to the onset of infection are imperative. To address resistance, there is an urgent need to address interconnected phenomenological silos: public health, environmental virulence, pathogen genomics, microbial biology, AI development, big data, bioinformatics analytics, the exploitation of multi-omics sciences, and the development and surveillance across licensed veterinary treatments and fit-for-purpose drugs. Innovation leading to new approaches for diagnostic, prevention, and cure activities development is crucial. Governments will be unable to resist multimodal infection treatment solutions for long, and we need to be ready to protect the prevention fallback strategies in the disease prevention toolbox at scale. We must also be able to offer antimicrobial alternatives of value. Responsive research involving the general public in the design and research priority setting is necessary, as is investigating the dynamics of infection, pro-inflammatory response variability, and psychological factors involved in morbidity and disability. Indicators of infectious diseases that reliably suggest that a strengthened or alternative treatment is required are important for human health to be incorporated into the Universal Health Coverage development agenda for those without illness. Progress on the development, validation, registration, and patent challenges of such multimodal drugs can be explored via existing initiatives globally. It is a matter of commitment, funding, and action. Turning words into action, knowledge into insights, and insights into value are the tasks that remain. Let's begin today [20, 21].

CONCLUSION

Antimicrobial resistance is an urgent global crisis requiring immediate, concerted action. It threatens public health, undermines medical advancements, and exacerbates healthcare inequalities. Effective mitigation demands robust international collaboration, integrating "One Health" strategies that connect human, animal, and environmental health. Governments, researchers, and policymakers must prioritize investment in diagnostic technologies, sustainable antimicrobial development, and equitable access to healthcare. Public education and responsible antimicrobial use are crucial to slowing resistance. Without comprehensive action, AMR risks reversing decades of medical progress, making common infections untreatable and threatening modern healthcare systems. Turning awareness into action is imperative—global health depends on it.

REFERENCES

1. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA. Antimicrobial resistance: a growing serious threat for global public health. InHealthcare 2023 Jul 5 (Vol. 11, No. 13, p. 1946). MDPI. mdpi.com
2. Aljeldah MM. Antimicrobial resistance and its spread is a global threat. Antibiotics. 2022 Aug 9;11(8):1082.
3. Saeed U, Insaf RA, Piracha ZZ, Tariq MN, Sohail A, Abbasi UA, Fida Rana MS, Gilani SS, Noor S, Noor E, Waheed Y. Crisis averted: a world united against the menace of multiple drug-resistant superbugs-pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

safeguard global antimicrobial arsenal. Frontiers in Microbiology. 2023 Nov 30;14:1270018. frontiersin.org

4. Kaur R, Sethi N. Phage therapy as an alternative treatment in the fight against AMR: Real-world problems and possible futures. InEmerging modalities in mitigation of antimicrobial resistance 2022 Jan 31 (pp. 357-374). Cham: Springer International Publishing. researchgate.net
5. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021 Oct 12;10(10):1310.
6. Aijaz M, Ahmad M, Ansari MA, Ahmad S. Antimicrobial Resistance in a Globalized World: Current Challenges and Future Perspectives. International Journal of Pharmaceutical Drug Design. 2023;1(1):7-22. researchgate.net
7. Mutekwe P. Resistance and repression in Zimbabwe: a case study of Zimplats mine workers. Review of African Political Economy. 2019 Apr 3;46(160):246-60.
8. Albernaz-Gonçalves R, Olmos G, Hötzel MJ. Exploring farmers' reasons for antibiotic use and misuse in pig farms in Brazil. Antibiotics. 2021 Mar 22;10(3):331.
9. Piddock LJ, Alimi Y, Anderson J, de Felice D, Moore CE, Røttingen JA, Skinner H, Beyer P. Advancing global antibiotic research, development and access. Nature Medicine. 2024 Sep;30(9):2432-43.
10. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, Saleem Z, Sneddon J, Hoxha I, Islam S, Mwita J. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life. 2021 Jun 7;11(6):528. mdpi.com
11. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, Lugova H, Dhingra S, Sharma P, Islam S, Mohammed I. Surveillance of antimicrobial resistance in low-and middle-income countries: a scattered picture. Antimicrobial Resistance & Infection Control. 2021 Dec;10:1-9. springer.com
12. Ahmad N, Joji RM, Shahid M. Evolution and implementation of One Health to control the dissemination of antibiotic-resistant bacteria and resistance genes: A review. Frontiers in Cellular and Infection Microbiology. 2023 Jan 16;12:1065796. frontiersin.org
13. Juliano RL. Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development. Science and Public Policy. 2013 Jun 1;40(3):393-405.
14. Suhandi V, Chen PS. Closed-loop supply chain inventory model in the pharmaceutical industry toward a circular economy. Journal of Cleaner Production. 2023 Jan 10;383:135474.
15. Mestrovic T, Aguilar GR, Swetschinski LR, Ikuta KS, Gray AP, Weaver ND, Han C, Wool EE, Hayoon AG, Hay SI, Dolecek C. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. The Lancet Public Health. 2022 Nov 1;7(11):e897-913. thelancet.com
16. Zhou N, Cheng Z, Zhang X, Lv C, Guo C, Liu H, Dong K, Zhang Y, Liu C, Chang YF, Chen S. Global antimicrobial resistance: a system-wide comprehensive investigation using the Global One Health Index. Infectious diseases of poverty. 2022 Aug 23;11(1):92. springer.com
17. Pezzani MD, Tornimbene B, Pessoa-Silva C, De Kraker M, Rizzardo S, Salerno ND, Harbarth S, Tacconelli E. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. Clinical Microbiology and Infection. 2021 May 1;27(5):687-96. sciencedirect.com
18. Coque TM, Cantón R, Pérez-Cobas AE, Fernández-de-Bobadilla MD, Baquero F. Antimicrobial resistance in the global health network: known unknowns and challenges for efficient responses in the 21st century. Microorganisms. 2023 Apr 17;11(4):1050. mdpi.com
19. Inoue H. Strategic approach for combating antimicrobial resistance (AMR). Global Health & Medicine. 2019 Dec 31;1(2):61-4.
20. Akram F, Imtiaz M, ul Haq I. Emergent crisis of antibiotic resistance: A silent pandemic threat to 21st century. Microbial pathogenesis. 2023 Jan 1;174:105923.
21. Pulingam T, Parumasivam T, Gazzali AM, Sulaiman AM, Chee JY, Lakshmanan M, Chin CF, Sudesh K. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. European Journal of Pharmaceutical Sciences. 2022 Mar 1;170:106103. sciencedirect.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CITE AS: Omutindo Nyakayo A. (2025). Understanding Antimicrobial Resistance: Global Responses Needed. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 5(2):7-11. https://doi.org/10.59298/RIJBAS/2025/52711

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.